HighVista Strategies’s Stoke Therapeutics STOK Stock Holding History

HighVista Strategies’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.01M	Sell	61,316 -1,301	-2%	-$41.8K	0.46%	60
2026 Q1	$2.04M	Sell	62,617 -52,922	-46%	-$1.74M	0.56%	59
2025 Q4	$3.67M	Buy	+115,539	New	+$3.47M	0.94%	35
2021 Q4	–	Sell	-47,594	Closed	-$1.21M	–	113
2021 Q3	$1.21M	Buy	+47,594	New	+$1.33M	0.8%	36
2021 Q2	–	Sell	-13,692	Closed	-$532K	–	140
2021 Q1	$532K	Sell	13,692 -3,976	-23%	-$226K	0.4%	67
2020 Q4	$1.09M	Buy	17,668 +586	+3%	+$26.9K	0.7%	23
2020 Q3	$572K	Sell	17,082 -652	-4%	-$18.6K	0.42%	30
2020 Q2	$423K	Buy	+17,734	New	+$421K	0.35%	48

Other funds holding STOK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HighVista Strategies's STOK Position: Q2 2026 in Review

HighVista Strategies reduced its Stoke Therapeutics (STOK) stake by 2.1% in Q2 2026, selling an estimated $41.8K and leaving 61,316 shares worth $2.01M. The position accounts for 0.46% of the portfolio, ranked #60.

HighVista Strategies first reported a position in STOK in Q2 2020 and has held it in 8 quarters since. The position peaked at $3.67M in Q4 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

HighVista Strategies held 61,316 shares of Stoke Therapeutics worth $2.01M as of Q2 2026.
HighVista Strategies sold 1,301 Stoke Therapeutics shares in Q2 2026, an estimated $41.8K.
Stoke Therapeutics made up 0.46% of HighVista Strategies's portfolio in Q2 2026, its #60 holding.
HighVista Strategies first reported a position in Stoke Therapeutics in Q2 2020 and has held it in 8 quarters since.
HighVista Strategies's Stoke Therapeutics position peaked at $3.67M in Q4 2025.
197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.